Sort   by:  
 Page size 
ProteomicsAssessment of Serological Early Biomarker Candidates for Lung Adenocarcinoma by using Multiple Reaction Monitoring-Mass Spectrometry
Purpose: Serum markers that enable diagnosis in the early stage of lung cancer have not been discovered. We have developed a LC-MRM-MS assay for the identification of potential early marker proteins for lung adenocarcinoma. Experimental design: LC-MRM-MS assay was used for measuring the level of 35 ...
ORGANISM(S): Homo Sapiens 
2021-01-24 | PXD014683 | panorama
ProteomicsTMTC1 promotes invasiveness of ovarian cancer
Ovarian cancer is the most lethal gynecological malignancy and is characterized by peritoneal disseminated metastasis. Although O-mannosyltransferase TMTC1 is highly expressed by ovarian cancer, its pathophysiologic role in ovarian cancer remains unclear. Here, immunohistochemistry showed that TMTC1...
ORGANISM(S): Homo sapiens (Human) 
2023-10-24 | PXD037907 | Pride
O-mannosylation Ovarian cancer Tmtc1 
ProteomicsTemporal regulation of Lsp1 O-GlcNAcylation and phosphorylation duringactivated Bcellsapoptosis
Here, we decipher the molecular mechanisms bridging B cell activation and apoptosis mediated by post-translational modification(PTM). We found that O-GlcNAcase inhibition enhances B cell activation and apoptosisinduced by B cell receptor (BCR)cross-linking. This proteome-scale analysis of the functi...
ORGANISM(S): Mus musculus (Mouse) 
2016-09-26 | PXD003788 | Pride
Phosphoproteome B cell O-glcnacylation Apoptosis 
ProteomicsPhosphoproteomic analyses reveal that galectin-1 augments the dynamics of B-cell receptor signaling
we applied label-free quantitative phosphoproteomic analysis to delineate the dynamics of galectin-1-induced signaling in comparison with the first systematic phosphorylation-mediated signaling network in B cell activation by anti-IgM treatment.
ORGANISM(S): Mus musculus (Mouse) 
2016-03-15 | PXD000762 | Pride
B-cell receptor Phosphoproteome Galectin-1 B-cell activation Lc-ms/ms 
ProteomicsBranched N-glycan of PD-L1 predicts immunotherapy responses in patients with recurrent/metastatic HNSCC
Immunotherapy has revolutionized cancer treatment, however, a reliable biomarker is missing. MGAT5-mediated PD-L1 glycosylation is critical for its interaction with PD-1. MGAT5 expression is a functional biomarker that predicts immunotherapy responses.
ORGANISM(S): Homo sapiens (Human) 
2025-05-06 | PXD045506 | Pride
Mgat5 Immunotherapy N-glycosylation Pd-l1 Head and neck squamous cell carcinoma (hnscc) 
UnknownE2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness.
Not available
S-EPMC6398890 | biostudies-literature
UnknownTREAT-AIS: A Multicenter National Registry.
Not available
S-EPMC12778707 | biostudies-literature
UnknownComparing Low- or Standard-Dose Alteplase in Endovascular Thrombectomy: Insights From a Nationwide Registry.
Not available
S-EPMC10896194 | biostudies-literature
UnknownThe Taiwan Precision Medicine Initiative provides a cohort for large-scale studies.
Not available
S-EPMC12675286 | biostudies-literature
Sort   by:  
 Page size